S&P 500   3,132.65 (-0.11%)
DOW   27,864.21 (-0.16%)
QQQ   203.93 (-0.07%)
AAPL   267.13 (+0.08%)
FB   201.72 (+0.19%)
MSFT   151.07 (-0.19%)
GOOGL   1,339.31 (-0.27%)
AMZN   1,745.16 (-0.25%)
CGC   21.19 (-0.47%)
NVDA   212.43 (+0.12%)
MU   47.17 (+1.53%)
BABA   200.05 (+0.66%)
GE   10.95 (-0.36%)
TSLA   341.02 (+0.44%)
T   37.98 (-0.16%)
AMD   38.99 (+0.15%)
ACB   2.62 (+0.00%)
F   9.00 (-0.22%)
PRI   135.47 (+0.09%)
NFLX   296.47 (-1.99%)
BAC   33.36 (-0.45%)
GILD   66.58 (-0.52%)
DIS   145.60 (-0.42%)
S&P 500   3,132.65 (-0.11%)
DOW   27,864.21 (-0.16%)
QQQ   203.93 (-0.07%)
AAPL   267.13 (+0.08%)
FB   201.72 (+0.19%)
MSFT   151.07 (-0.19%)
GOOGL   1,339.31 (-0.27%)
AMZN   1,745.16 (-0.25%)
CGC   21.19 (-0.47%)
NVDA   212.43 (+0.12%)
MU   47.17 (+1.53%)
BABA   200.05 (+0.66%)
GE   10.95 (-0.36%)
TSLA   341.02 (+0.44%)
T   37.98 (-0.16%)
AMD   38.99 (+0.15%)
ACB   2.62 (+0.00%)
F   9.00 (-0.22%)
PRI   135.47 (+0.09%)
NFLX   296.47 (-1.99%)
BAC   33.36 (-0.45%)
GILD   66.58 (-0.52%)
DIS   145.60 (-0.42%)
S&P 500   3,132.65 (-0.11%)
DOW   27,864.21 (-0.16%)
QQQ   203.93 (-0.07%)
AAPL   267.13 (+0.08%)
FB   201.72 (+0.19%)
MSFT   151.07 (-0.19%)
GOOGL   1,339.31 (-0.27%)
AMZN   1,745.16 (-0.25%)
CGC   21.19 (-0.47%)
NVDA   212.43 (+0.12%)
MU   47.17 (+1.53%)
BABA   200.05 (+0.66%)
GE   10.95 (-0.36%)
TSLA   341.02 (+0.44%)
T   37.98 (-0.16%)
AMD   38.99 (+0.15%)
ACB   2.62 (+0.00%)
F   9.00 (-0.22%)
PRI   135.47 (+0.09%)
NFLX   296.47 (-1.99%)
BAC   33.36 (-0.45%)
GILD   66.58 (-0.52%)
DIS   145.60 (-0.42%)
S&P 500   3,132.65 (-0.11%)
DOW   27,864.21 (-0.16%)
QQQ   203.93 (-0.07%)
AAPL   267.13 (+0.08%)
FB   201.72 (+0.19%)
MSFT   151.07 (-0.19%)
GOOGL   1,339.31 (-0.27%)
AMZN   1,745.16 (-0.25%)
CGC   21.19 (-0.47%)
NVDA   212.43 (+0.12%)
MU   47.17 (+1.53%)
BABA   200.05 (+0.66%)
GE   10.95 (-0.36%)
TSLA   341.02 (+0.44%)
T   37.98 (-0.16%)
AMD   38.99 (+0.15%)
ACB   2.62 (+0.00%)
F   9.00 (-0.22%)
PRI   135.47 (+0.09%)
NFLX   296.47 (-1.99%)
BAC   33.36 (-0.45%)
GILD   66.58 (-0.52%)
DIS   145.60 (-0.42%)
Log in

NASDAQ:ABAX - Abaxis Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$83.00
0.00 (0.00 %)
(As of 08/1/2018)
Today's Range
$83.00
Now: $83.00
$83.00
50-Day Range N/A
52-Week Range
$43.66
Now: $83.00
$83.98
VolumeN/A
Average Volume167,754 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Abaxis, Inc develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents. Read More…

Industry, Sector and Symbol

Industry Measuring & controlling devices, not elsewhere classified
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ABAX
CUSIP00256710
Phone510-675-6500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Receive ABAX News and Ratings via Email

Sign-up to receive the latest news and ratings for ABAX and its competitors with MarketBeat's FREE daily newsletter.


Abaxis (NASDAQ:ABAX) Frequently Asked Questions

What is Abaxis' stock symbol?

Abaxis trades on the NASDAQ under the ticker symbol "ABAX."

How were Abaxis' earnings last quarter?

Abaxis Inc (NASDAQ:ABAX) issued its earnings results on Thursday, April, 26th. The medical research company reported $0.42 earnings per share for the quarter, topping analysts' consensus estimates of $0.32 by $0.10. The medical research company had revenue of $67.90 million for the quarter, compared to analyst estimates of $66.02 million. Abaxis's revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.33 earnings per share. View Abaxis' Earnings History.

Has Abaxis been receiving favorable news coverage?

Media coverage about ABAX stock has been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Abaxis earned a news impact score of -2.0 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Abaxis.

Who are some of Abaxis' key competitors?

What other stocks do shareholders of Abaxis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abaxis investors own include Skyworks Solutions (SWKS), Wells Fargo & Co (WFC), Akorn (AKRX), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), NXP Semiconductors (NXPI), Pacira Biosciences (PCRX), Abbott Laboratories (ABT), Allergan (AGN) and Celgene (CELG).

Who are Abaxis' key executives?

Abaxis' management team includes the folowing people:
  • Mr. Clinton H. Severson, Chairman & CEO (Age 70)
  • Mr. Donald P. Wood, Pres & COO (Age 66)
  • Mr. Ross Taylor Jr., CFO, VP of Fin. & Sec. (Age 55)
  • Dr. Kenneth P. Aron Ph.D., Chief Technology Officer (Age 65)
  • Dr. Craig M. Tockman DVM, VP of Animal Health Sales and Marketing - North America (Age 58)

What is Abaxis' stock price today?

One share of ABAX stock can currently be purchased for approximately $83.00.

What is Abaxis' official website?

The official website for Abaxis is http://www.abaxis.com/.

How can I contact Abaxis?

Abaxis' mailing address is 3240 WHIPPLE ROAD, UNION CITY CA, 94587. The medical research company can be reached via phone at 510-675-6500 or via email at [email protected]


MarketBeat Community Rating for Abaxis (NASDAQ ABAX)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  230 (Vote Outperform)
Underperform Votes:  332 (Vote Underperform)
Total Votes:  562
MarketBeat's community ratings are surveys of what our community members think about Abaxis and other stocks. Vote "Outperform" if you believe ABAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel